Study: Lilly's Retatrutide Cuts Weight, Knee Pain and Sleep Apnea
The Spin
Pro-industry narrative
Obesity, diabetes and fatty liver are biological diseases, not moral failings, and hitting three metabolic pathways at once finally matches the size of the problem. Weight loss that deep, plus easier knees, quieter sleep apnea and blood sugar pushed back under the diabetes line, means fewer heart attacks, dialysis chairs and transplant lists. Medicine like this doesn't excuse lifestyle change — it makes it possible.
Industry-critical narrative
Dramatic weight-loss means nothing if the heart underneath keeps failing, and a trial where the sickest patients on the drug logged more cardiac events than those on placebo deserves hard answers, not a victory lap. The full safety picture, from pancreatitis to strange skin sensations, is still unknown. Meanwhile an unapproved peptide is being mixed at kitchen tables from sketchy vendors while regulators mail letters nobody fears.